sacituzumab govitecan-hziy
Gilead Sharing Keytruda, Trodelvy Triple-Negative Breast Cancer Data With Regulators
In a Phase III trial, the Keytruda-Trodelvy combo improved progression-free survival in patients with PD-L1-positive tumors compared to Keytruda-chemo.
Ideaya Begins Trial Expansion of IDE397, Trodelvy in MTAP-Deletion Urothelial Cancer
The firm is evaluating its MAT2A inhibitor IDE397 with Trodelvy in urothelial and non-small cell lung cancers with MTAP deletions.
Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.
Gilead has high hopes that anito-cel, a multiple myeloma cell therapy it is developing with Arcellx, can bolster its cell therapy franchise.
Gilead Optimistic About 11 Percent Q2 Growth in Cell Therapy Sales but Readying for Competition
Premium
The firm is working with providers to expand the use of Yescarta and Tecartus as competition from other CAR T-cell therapies and bispecifics heats up.
Aug 4, 2023
Apr 28, 2023
Gilead Q1 Oncology Segment Sales Jump 59 Percent
Feb 3, 2023
Oct 28, 2022
Sep 29, 2022
Apr 29, 2022